Brief: Corbus Pharmaceuticals Announces Broad Alignment With FDA On Registration Path For Crb-701 In Second-Line Hnscc And Cervical Cancer
07/04/2026 13:05
April 7 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O: CORBUS PHARMACEUTICALS ANNOUNCES BROAD ALIGNMENT WITH FDA ON REGISTRATION PATH FOR CRB-701 IN SECOND-LINE HNSCC AND CERVICAL CANCER CORBUS PHARMACEUTICALS HOLDINGS INC - TO CONTINUE FDA INTERACTIONS TO FINALIZE REGISTRATION STUDY PROTOCOLS Source text: ID:nGNX15QVGn Further company coverage: CRBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study